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ABSTRACT: The progression of hepatic fibrosis can lead to
cirrhosis and hepatic failure, but the development of antifibrotic
drugs have faced the challenges of poor effectiveness and targeted
specificity. Herein, a theranostic strategy was carried to encapsulate a
natural medicine (Quercetin, QR) into hepatitis B core (HBc)
protein nanocages (NCs) for imaging and targeted treatment of
hepatic fibrosis. It was noted that nanoparticles (RGD-HBc/QR)
with surface-displayed RGD targeting ligand exhibit a rather high
selectivity toward activated HSCs via the binding affinity with
integrin αvβ3, and an efficient inhibition of proliferation and
activation of hepatic stellate cells (HSCs) in vitro and in vivo.
Once encapsulated in quercetin−gadolinium complex and/or labeled with the NIR fluorescent probes (Cy5.5), the resulting
nanoparticles (RGD-HBc/QGd) show great potential as NIR fluorescent and magnetic resonance imaging contrast agents for
hepatic fibrosis in vivo. Therefore, the multifunctional integrin-targeted nanoparticles could selectively deliver QR to the
activated HSCs, and may provide an effective antifibrotic theranostic strategy.
■ INTRODUCTION
The liver is one of the most important organs that plays a
central role in detoxifying and transforming chemicals, which
consequently puts the liver in the pathway of exposure to
harmful agents and increases its susceptibility to diseases. Over
10% of the world population suffers from liver diseases.1
Among all liver ailments, fibrosis has emerged as a major health
concern. It is the consequence of a sustained wound healing
response to a chronic liver injury from a variety of causes
including viral, autoimmune, drug induced, cholestatic, and
metabolic diseases.2 Fibrosis can lead to cirrhosis and
ultimately to hepatocellular carcinoma and irreversible liver
failure.3
To date, there is no specific and effective antifibrotic therapy
on record, and otherwise varieties of complications are caused
by synthetic drugs.4 Since herbal medicines are now replacing
synthetic pharmaceuticals and looked upon as sources of novel
bioactive substances, a number of herbal derivatives show
promising effects against hepatic fibrosis either experimentally
in cell culture (in vitro) and in animals models (in vivo) or
even in clinical trials.5 Quercetin (QR), one of the most
abundant natural flavonoids in human diet with no side effects,
exhibits various pharmacological properties such as antiox-
idative and anti-inflammatory activities under pathological
circumstances.6 It was found that quercetin could significantly
suppress the activation of the fibroblasts, partly because of its
ability to downregulate the NF-κB signal transduction pathway
which has critical functions in the regulation of inflammatory
responses via multiple mechanisms.7 It was also found that QR
inhibited inflammation induced by carbon tetrachloride
(CCl4) through its antioxidant activity and regulation of
TLR2/TLR4 and MAPK/NF-kappa B signal transduction
pathways.8
Hepatic fibrogenesis is a complex process involving a variety
of pathogenic and host-specific signal transduction processes,
and it is characterized by immoderate production and
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deposition of extracellular matrix (ECM).9 Activated hepatic
stellate cells (aHSCs), portal fibroblasts, and myofibroblasts of
bone marrow origin have been identified as the major collagen
producing cells.10 When the liver is damaged by inflammatory,
hepatitis viruses, or mechanical processes, hepatic stellate cells
(HSCs) can be activated to produce activating cytokines which
promote cell proliferation.11 The aHSCs may promote the
proliferation of myofibroblasts and irreversible ECM deposi-
tion through paracrine or autocrine mechanisms.12 Both HSCs
activation and their number alteration can result in fibro-
genesis. Although the HSCs phenotype is difficult to reverse
after activation, reversal is not impossible. Recent studies
support the hypothesis that liver fibrosis can be modulated by
promoting apoptosis of aHSCs. Considering that the liver is a
nonimmunological organ, and engaged primarily in metabo-
lism, nutrient storage, and detoxification, targeting aHSCs has
thus become an attractive strategy for treatment of hepatic
fibrosis.13,14 The aHSCs-targeted delivery strategy may not
only induce aHSCs apoptosis and increase the antifibrotic
action, but also improve the microenvironment, prolong drug
release, and reverse drug resistance, and reduce the toxicity.
Moreover, it has been found that integrin αvβ3 could be
expressed by HSCs during their activation, and the expression
correlates well with the degree of hepatic fibrosis, which is a
specifically biological targets on aHSCs for treatment of
hepatic fibrosis.15,16
Few of clinic studies have demonstrated a reversal of hepatic
fibrosis in early stages, thus early diagnosis is necessary and
important for patients to avoid exacerbation and reduce the
mortality rate of patients.17 Despite biopsy is a gold standard
for hepatic fibrosis in clinical diagnosis, it is an invasive
procedure with a small but significant risk of life-threatening
complications.18 Therefore, it is important to develop a safe,
reliable, and noninvasive screening method for precise
detection and evaluation of hepatic fibrosis. Magnetic
resonance imaging (MRI) is a powerful and important imaging
modality in clinical settings because of its highest spatial
resolution to soft tissues.19 Near-infrared fluorescence (NIR
FL) bioimaging technology has attracted a great amount of
attention due to the deep tissue penetration, low background
fluorescence interference, and minimal biological damage.20
Therefore, dual modal MR/NIR imaging probe could be an
attractive combination for precise diagnosis of hepatic fibrosis,
which allows full body screening of the probe uptake by MRI
and quantification by NIR.
A plethora of nanomaterials has been developed to address
some limitations of conventional drug delivery systems, and
tried to revolutionize the diagnosis and treatment of several
diseases, in particular by selectively directing therapeutic
agents to the target tissues and cells.21 In recent years, a lot
of nanomaterials-based medicines have been used to resist
variable liver diseases, such as liver cancer,22 drug-induced
hepatic damage,23 and hepatic ischemia-reperfusion injury.24
Among the many nanomaterials that are being developed for
therapeutic applications, protein nanocages (NCs) are the
most powerful and safe carriers, hold unique features including
excellent biocompatibility, biodegradation, efficient cell per-
meability, and suitable pharmacokinetics, which make them
highly attractive as ideal drug delivery systems for pharma-
ceuticals and/or imaging probes.25 The self-assembling
hepatitis B core protein (HBc) NCs are the most flexible
protein engineering platforms which caged the structure of
both the interior and the exterior, which could be easily
engineered though chemical or genetical modifications.26 HBc
NCs are composed of natural biological building blocks, share
important features such as facile production, the capacity to
cross the biological barrier, as well as the biocompatibility and
biodegradability in mammals, which make them excellent
choices for targeted drug delivery.27
Herein, we report the design of the theranostic QR
nanoparticles based on HBc NCs, allowing dual modal
(NIR/MR) molecular imaging, and targeted therapy of hepatic
fibrosis. To overcome the poor aqueous solubility and
bioavailability of QR, the sulfobutylether-β-cyclodextrin
(SBE-β-CD) as hydrophobic pockets was introduced through
electrostatic interaction inside the protein nanocages (Scheme
1). The self-assembling nanocages with surface-displayed RGD
targeting ligands (RGD-HBc/QR) exhibit a rather high
selectivity toward activated HSCs via the binding affinity
with integrin αvβ3. It was noted that RGD-HBc/QR NCs
exhibit excellent biocompatibilities and specific accumulation
in fibrotic livers in CCl4-induced mice models but not in
healthy livers, and efficiently blocking of hepatic fibrogenesis.
Once encapsulated quercetin−gadolinium complex (QR-Gd)
and/or labeled with the NIR fluorescent probe (Cy5.5), the
resulting nanoparticles (RGD-HBc/QGd) exhibited a poten-
tial for use as a NIR FL and MR imaging contrast agent for
hepatic fibrosis in vivo. The prepared RGD-HBc/QGd realized
dual modal imaging and significant antifibrotic effects,
therefore it posed a hopeful potential for further biomedical
and clinical applications.
■ RESULTS AND DISCUSSION
Characterization of RGD-HBc/QR and RGD-HBc/QGd
NCs. As a member of nature-derived protein nanocage, HBc
NCs could be modified easily and precisely through genetic
Scheme 1. (A) Encapsulation of QR/QGd to RGD-HBc
NCs through Self-Assembled Process and (B) Theranostic
Property of RGD-HBc/QGd NCs: In vivo FL and MR
Imaging of Fibrotic Liver (Left) and Liver Regeneration by
aHSC Proliferation (Right)
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methods, and had been demonstrated to be a flexible
nanoplatform for drug delivery. To enhance the affinity with
fibrotic liver, the targeting peptide (RGD) was genetically
introduced to the major immune region (MIR) of the full
length HBc-183 protein between residues 78 and 82 which
were fully exposed to the exterior surface. RGD-HBc was
expressed in E. coli. The SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) of purified RGD-HBc protein yielded a
single band, which agreed with corresponding to molecular
weight of 24 kDa (Figure 1A). Negatively stained transmission
electron microscopic image (TEM) revealed that the
morphology of RGD-HBc NCs were monodispersed and
well-defined spheres (Figure 1B), indicating that RGD-HBc
proteins could participate in self-assembly.
To effectively load hydrophobic drugs into RGD-HBc NCs,
SBE-β-CD was introduced to improve the solubility of QR.
The SBE-β-CD possesses high water solubility and negative
charge at the outer edge and hydrophobic in the inner cavity,
and can be used as envelope of the natural hydrophobic
quercetin. The nucleic acid-binding sites of HBc NCs provided
positively charged inner cavity, allowing to encapsulate
negative charged cargos through the electrostatic interactions.
Accordingly, the SBE-β-CD loaded with quercetin could be
further encapsulated into the cavities of RGD-HBc NCs in the
process of reassembling (Figure S1 of the Supporting
Information, SI). Since the complex photodynamical behavior
inside the protein and the intermolecular interactions between
trapped QR and amino acid residues would affect the
absorption spectrum,28 the blue shift in UV−vis absorption
spectra of RGD-HBc/CD/QR NCs means the successful
encapsulation of QR by HBc NCs. Through calculations, the
loading efficiency of QR in RGD-HBc/CD/QR NCs was
10.09 ± 2.56%, the loading capacity was 16.32 ± 1.75%, and
the amount of encapsulated QR was 1996 ± 27 per nanocage.
On the basis of the TEM images, a similar morphology of
RGD-HBc/QR NCs to that of RGD-HBc NCs was observed
(Figure 1C). The average diameter of nanoparticles counted
and calculated from the transmission electron microscope
(TEM) is 29.6 ± 3.1 nm. Besides, the particle size and the
distribution of the RGD-HBc and RGD-HBc/QR NCs were
also measured by dynamic light scattering (DLS). The average
diameter of the RGD-HBc/QR in water was 32.5 ± 4.1 nm
(Figure 1D), which is in good agreement with the diameter of
RGD-HBc NCs. As illustrated in Figure 1E, the coelution
profiles programmed by high performance liquid chromatog-
raphy (HPLC) of RGD-HBc NCs (typical absorption peak at
280 nm) and QR (typical absorption peak at 374 nm) after 5
min demonstrated the efficient encapsulation of QR into RGD-
HBc NCs. These results revealed that encapsulation of β-CD-
QR complex into the cavity of RGD-HBc NCs did not
significantly interfere with the self-assembly or alter the cage
nanostructure. The photograph of β-CD-QR complex
encapsulated RGD-HBc NCs was shown in Figure 1F.
In addition, we also tried to encapsulate the quercetin−
gadolinium complex with MRI T1-enhancing properties into
RGD-HBc NCs through SBE-β-CD. RGD-HBc/QGd NCs
were further characterized by TEM and DLS. The particle size
and morphology of RGD-HBc/QGd NCs were comparable to
that of RGD-HBc NCs (Figures S2 and S3).
Previous studies29 have reported that quercetin−gadolinium
complex could be a novel MRI contrast agent. To validate the
MRI contrast of RGD-HBc/QGd NCs, the MRI signal in vitro
was examined. The typical T1 weighted spin−echo MRI images
recorded for RGD-HBc/QGd NCs at different Gd concen-
trations in water was shown in Figure 2A. It can be observed
that there was a clearly evident positive contrast enhancement
of MRI signals, as demonstrated by the increased brightness.
The T1 relaxivity curves for RGD-HBc/QGd NCs were shown
in Figure 2B. The r1 value of RGD-HBc/QGd NCs was 4.77
mM−1 s−1, which was better than commercial T1 contrast agent
Gd-DOTA (r1 = 3.83 mM
−1·s−1).30 These results indicated
that NCs could be used as a candidate of T1 MR imaging
contrast agent.
Cytotoxicity and Cellular Uptake. To evaluate the
impact of RGD-HBc and RGD-HBc/CD NCs on the viability
of HSCs and aHSCs, MTT assay was performed with different
concentrations of these carriers after incubation for 24 h,
respectively. The cell viabilities in the concentration range
from 25 to 300 μg mL−1 were more than 80% in both RGD-
HBc NCs and RGD-HBc/CD NCs groups (Figure S4). The
RGD-HBc and RGD-HBc/CD NCs presumably presented
excellent biocompatibility rather than significant cytotoxicity.
In fact, this was the groundwork laid for imaging and treatment
in vivo, subsequently.
Acetaldehyde has been reported to make HSCs rapidly
activate and transdifferentiate to proliferation.31 Herein, to
demonstrate the targeting ability of the RGD-HBc NCs to
Figure 1. Characterization of RGD-HBc NCs. (A) SDS-PAGE
analysis of RGD-HBc NCs and HBc NCs. Representative TEM image
of (B) RGD-HBc NCs and (C) RGD-HBc/QR NCS. (D) DLS
measurement of RGD-HBc NCs and RGD-HBc/QR NCs. (E) Size
exclusion elution profiles of RGD-HBc/QR NCs by HPLC analysis
with size-exclusion chromatography (absorbance at 280 and 374 nm).
(F) Photograph of RGD-HBc NCs and RGD-HBc/QR NCs.
Figure 2. (A) T1 weighted spin−echo MR images recorded for
aqueous solutions of RGD-HBc/QGd NCs with different concen-
trations of Gd. Images were obtained at 1.5 T (TR/TE 1/4 600/9
ms) at room temperature. (B) T1 relaxation rate (1/T1) as a function
of Gd concentration for RGD-HBc/QGd NCs.
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aHSCs, which were obtained by cocultivation with acetalde-
hyde in vitro in advance, the cellular internalization process of
RGDHBc NCs was carried out. Cy5.5-labeled RGD-HBc NCs
were incubated with HSCs and aHSCs for 0.3, 1, 2, and 4 h,
respectively. In Figure 3A, the fluorescence signals detected by
flow cytometry suggested that RGD-HBc NCs were more
prone to be taken up by aHSCs which pretreated with
acetaldehyde compared to HSCs without treatment. Moreover,
this result could also be confirmed by the results of the
confocal laser scanning microscope images (CLSM). As shown
in Figure 3B, C, the blue fluorescence was from DAPI-stained
cell nuclei while the red fluorescence was from Cy5.5-labeled
RGD-HBc NCs. Overall, the merge area indicated that,
although the uptake amount was added over time, compared
with HSCs cells, the RGD-HBc NCs could bind to the aHSCs
faster. On the basis of the fluorescence intensity data of the
merge (Figure S5), it was worth noting that the uptake
intensity of aHSCs was almost 1.78 times that of HSCs at 4 h.
The results thus indicated that RGD peptides, displayed on the
surface-exposed spikes of HBc NCs, could promote the cell
uptake under recognition of cell surface integrin αvβ3 due to
the high expression of integrin αvβ3 in aHSCs.
In Vitro Antifibrotic Efficacy of RGD-HBc/QR NCs. The
state of hepatic stellate cells transferred from quiescent to
activated was the central event in the liver fibrosis when the
liver damaged. The flavonoid quercetin has displayed anti-
inflammatory and antifibrotic effects, and many previous
studies have reported that quercetin could inhibit pulmonary
fibrosis via preventing activation of HSCs. To evaluate the
effect of RGD-HBc/QR NCs on liver fibrosis, cell prolifer-
ation, and α smooth muscle actin (α-SMA) expression in
HSCs were determined.
A carboxyfluorescein succinimidyl ester (CFSE) prolifer-
ation assay was performed to measure cell proliferation. CFSE-
labeled aHSCs were incubated with RGD-HBc/QR for 24 h,
and then detected the dye dilution by flow cytometry. As
shown in Figure 4A, a more robust proliferation of aHSCs was
observed, while RGD-HBc/QR-treated aHSCs had 3.3 times
and 1.7 times lower proliferation than those of untreated
aHSCs and HSCs, respectively (Figure 4B). The results
suggested that RGD-HBc/QR NCs significantly inhibited
proliferation of aHSCs.
The protein expression of α-SMA, which is a special marker
of activated HSCs, was detected by Western blotting. As
shown in Figure 4C, Western blots results exhibited that RGD-
HBc/QR treatment reduced the protein expression of α-SMA.
Furthermore, computer assisted semiquantitative analysis
(Figure 4D) showed significant dose-dependent decrease in
the expression of α-SMA protein. It was noted that RGD-HBc/
QR could rapidly and efficiently deliver drugs to targeted cells
and inhibit the activation of HSCss.
In Vivo Hepatic Fibrosis Targeting of RGD-HBc/QR
NCs. The precise biodistribution of RGD-HBc/QR was
evaluated respectively in liver fibrotic mice at the selected
time points after intravenous injection of Cy5.5-labeled RGD-
HBc/QR NCs. After CCl4 treatment for 8 weeks, mice could
show marked fibrosis in the liver. In Figure 5A, RGD-HBc/QR
was rapidly cleared from the blood by the kidney in healthy
mice. In contrast, RGD-HBc/QR was significantly accumu-
lated in the fibrotic liver for a relatively long time, which could
be associated with the high affinity of RGD-HBc/QR with
aHSCs (Figure 5B, C). Besides, the fluorescence signal
intensity of ex vivo livers of mice were evidently stronger in
the fibrotic group (Figure 5E) than that in the normal group
(Figure 5D) at indicated time points (0.3, 2, and 12 h) after
intravenous injection. These results suggested that RGD-HBc/
QR NCs can be effectively retained in fibrotic livers due to
active targeting mediated by RGD.
In Vivo Antifibrotic Efficacy of RGD-HBc/QR NCs. The
in vivo activity of RGD-HBc/QR NCs was assessed in the
fibrotic group, which was characterized by the obvious fibrosis
phenotype from the following analyses. In the fibrotic group,
RGD-HBc/QR treatment attenuated the fibrotic level of the
fibrotic tissue, the appearance of degenerated hepatocytes, and
inflammatory cell infiltration (Figure S5A). Hydroxyproline
content is an objective measure of liver fibrosis. The
quantification of tissue hydroxyproline (Figure S5B) revealed
Figure 3. In vitro cellular uptake: HSCs and aHSCs incubated with
Cy5.5-labeled RGD-HBc NCs and measured by flow cytometry (A);
CLSM of HSCs (B); and aHSCs (C) incubated with Cy5.5-labeled
RGD-HBc NCs at the selected time points, respectively. The scale bar
is 20 μm.
Figure 4. Effects of RGD-HBc/QR NCs on aHSCs in vitro. (A)
Representative flow cytometry histograms of CFSE-labeled HSCs,
aHSCs, and RGD-HBc/QR NCs-treated aHSCs (aHSCs+NCs)
proliferations and (B) the quantitative comparison of the prolifer-
ations. (C) Western blot analysis and (D) the quantitative
comparison of α-SMA expression in aHSCs cultivated with RGD-
HBc/QR NCs at different concentrations of QR (0, 0.5, 0.1, 0.5 μM)
for 24 h. The results were normalized relative to expression GAPDH.
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more than a 1.5-fold reduction for RGD-HBc/QR NCs treated
mice compared to fibrotic group. Alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) are two of the
enzymes central to detect or monitor liver damage. As shown
in Figure S5C−E, the enzyme levels of ALT and AST were
significantly decreased in the treated group compared to
fibrotic group.
The protein levels of α-SMA were measured by
immunohistochemistry. As illustrated in Figure 6A, CCl4 up-
regulated the expression of α-SMA, while treatment with
RGD-HBc/QR NCs could obviously suppress this increase,
from 1.96% ± 0.66% to 1.09% ± 0.33% (p < 0.05). Analyses of
sirius red stained and masson stained areas, as well as
histopathology, also confirmed that RGD-HBc/QR NCs
exerted a significantly superior inhibitory effect against
activated HSCs (Figure 6B and C). Pathological analysis was
performed and is shown in Figure S6, no toxicity was observed
in other organs (heart, spleen, lung, and kidneys) of the mice
in the three groups (normal, fibrotic, treated) after RGD-HBc/
QR NCs injection.
In Vivo Magnetic Resonance (MR) Imaging. To
evaluate the efficacy of RGD-HBc/QGd NCs in enhancing
MRI contrast in hepatic fibrosis diagnosis and monitor the
treatment of RGD-HBc/QR NCs, in vivo MR images were
recorded before and after administration of RGD-HBc/QGd
with a dose of 0.05 mmol Gd/kg of body weight. Compared
with the healthy livers of the normal group (Figure 7A), the
fibrotic liver tissues (Figure 7B) appear as a brighter area on
the T1-weighted image at 1 h after injection, indicating that
RGD-HBc/QGd NCs could specifically target fibrotic liver,
which were consistent with the observations from fluorescence
imaging. Since fibrotic livers contain many activated HSCs
which express integrin αvβ3, RGD-HBc/QGd NCs could
accumulate more efficiently than in healthy liver, due to the
specific interaction between targeted-ligand RGD and integrin
αvβ3. Normally, compared with the normal surrounding tissue,
fibrotic livers tend to present high RGD-HBc/QGd NCs
uptake. Such a difference caused a dramatic signal increase in
hepatic lesion and was demonstrated as an optical contrast
between fibrosis and normal group tissue on T1-weighted MR
images. In contrast with the normal group, the liver tissues of
the treated group appeared hypointense after HBc/QGd NCs
injection (Figure 7C), indicating that RGD-HBc/QR NCs
treatment had significantly reduced the liver fibrosis. It could
also be illustrated by the quantification of MRI in Figure 7D.
Figure 5. In vivo images of the mice and tissues. The mice in normal
group (A) and fibrotic group (B) were i.v. injected with Cy5.5-labeled
RGD-HBc NCs. (C) Quantification of the fluorescence intensity in
the liver regions (dashed line) of the two groups. The ex vivo images
of major organs (heart, liver, spleen, lung, and kidneys) of the mice in
normal group (D) and fibrotic group (E) after i.v. injection of Cy5.5-
labeled RGD-HBc NCs at selected time points. (F) Quantification of
the fluorescence intensity of the ex vivo livers. * p < 0.05 compared
with normal group.
Figure 6. Effects of RGD-HBc/QR NCs on liver fibrosis in the fibrotic group. (A) Liver sections were immunostained for α-SMA to assess HSCs
activation. Original magnification, ×400 (n = 5). (B) Liver sections were stained with Sirius red to assess collagen deposition. Original
magnification, ×400, (n = 5). (C) Fibrillar collagen was evaluated by masson staining of liver sections. Original magnification, ×400, (n = 5).
Masson staining, Sirius red-stained areas, and α-SMA, the areas were analyzed using the Image-pro plus 5.0 software.
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All the results in this section illustrate that RGD-HBc/QGd
NCs could not only be used as an MRI contrast agent for
fibrosis, but also as a tracer for treatment monitoring.
■ CONCLUSIONS
In summary, the present study demonstrates that RGD-HBc/
QR NCs with excellent biodegradability and biocompatibility
can improve the bioavailability of poorly soluble QR, and
significantly inhibit hepatic fibrosis. RGD-HBc/QR NCs can
be taken up by aHSCs via the binding affinity with integrin
αvβ3, specifically accumulate in fibrotic liver in CCl4-induced
mice models, and remarkably suppress the activation of HSCs
both in vivo and in vitro. Furthermore, RGD-HBc/QR NCs
are also a kind of high-performance MR/NIR imaging contrast
agent with high T1 relaxivity value and NIR fluorescence
through encapsulating Gd contrast agents and labeling NIR-
dyes to support noninvasive in vivo evaluation of hepatic
fibrosis. Collectively, our work not only develops a potential
targeted theranostic agent but also provides a novel strategy for
the treatment of fibrotic conditions.
■ MATERIALS AND METHODS
Preparation and Characterization of the RGD-HBc
NCs. The expression and purification of the RGD-HBc NCs
were achieved similarly to that described in a previous report.32
Briefly, the plasmid genetically modified was transformed into
an E. coli strain, which was expanded and cultured in an LB
medium (Sangon Biotech) at 37 °C until the OD 600 nm
reached 0.6−0.8. After adding Isopropyl β-D-thiogalactoside
(IPTG, 0.1 mM, Aladdin), it was incubated at 17 °C for 18 h.
Then, bacteria were collected by centrifugation at 5000 rpm
and lysed on ice by sonication. For further purification, DEAE
ion-exchange chromatography was carried out after precipitat-
ing the suspension with saturated (NH4)2SO4 (BBI). At last,
the proteins were collected and stored at 4 °C. Molecular
weight and purity of protein were analyzed by SDS-PAGE
electrophoresis and the morphology of the RGD-HBc NCs was
observed by TEM (Tecnai G2 Spirit, FEI, U.S.A.). The size
and zeta potential of the RGD-HBc NCs then were measured
by DLS (Malvern Zetasizer Nano ZS, Malvern Instruments,
Ltd., U.K.).
Synthesis of Quercetin−Gadolinium(III) Complex.
The quercetin−gadolinium(III) complex was synthesized
following the previous method.29 Generally, quercetin
dihydrate (0.1 M, Sinopharm Chemical Reagent) was
dissolved in 25 mL of methanol and 0.1 M of NaOH was
added to the solution. Then, a methanol solution (25 mL)
dissolved cerium chloride (0.1 M) was slowly added. The
mixture solution was stirred at room temperature for about 6 h.
The solvent was collected by rotary evaporator and washed
with 1:1 chloroform/n-butyl alcohol and water to remove the
unreacted molecules, followed by vacuum drying overnight to
obtain quercetin−gadolinium(III) (QGd) complex.
Drug Packaging. The inclusion complex of SBE-β-CD
(Zhiyuan Biotechnology) was prepared by ultrasonication after
quercetin (15 mmol) was added into the SBE-β-CD aqueous
solution (15 M). The RGD-HBc NCs were incubated in the
depolymerization buffer for 1 h, and then the inclusion
complex obtained above was loaded into the depolymerized
solution and incubated together for another hour. The
mixtures were dialyzed in assembling buffer at 4 °C for 24 h
(the molecular weight cutoff (MWCO) of dialysis tubing is
3500 Da for the first 12-h, and the MWCO of dialysis tubing is
100 kDa for the second 12-h) to acquire the reassembled
nanocages. The drug loading was measured by UV
spectrophotometer (UV-2550, Shimadzu, Japan), the morphol-
ogy and particle size of the nanoparticles packaged with drug
were received by TEM and DLS. The amount of encapsulated
QR per nanocage was calculated as molar ratio (MR) following
the formula below:
= W M W MMR ( / )/( / )loaded QR QR NCs NCs
where Wloaded QR is the mass of the QR encapsulated in RGD-
HBc NCs, and WQR is the mass of QR input.
CFSE Proliferation Assay. Hepatic stellate cells were
purchased and maintained in DMEM (Hyclone) containing
10% FBS (ABW), 50 unites mL−1 penicillin/streptomycin
(Hyclone) at 37 °C in a humidified 5% CO2 atmosphere.
Activated HSCs cells were obtained by stimulating HSCs with
200 mM of acetaldehyde for 48 h.31 HSCs and aHSCs were
coincubated with RGD-HBc/QR NCs and collected after
removing PBS, CFSE working solution (5 μM working
solution in DMEM medium) was added incubating for 10
min. Then half the volume of precooled calf serum was added
to stop labeling, standing for 10 min, followed by washing
twice with PBS, and resuspension with 1 mL complete
medium. Cells were placed on a flow cytometer to measure
fluorescence intensity.
Animal Experiments. All animal studies were executed in
accordance with IACUC approved procedure at Xiamen
University, China (Animal ethics review number: XMU-
LAC20160002). Male BABL-c mice (5−6 week, 16−20 g),
purchased from Beijing Vital River Laboratories Animal
Technology Co., Ltd. by the Laboratory Animal Center of
Figure 7. MR images recorded for mice in different groups. Normal
liver (A), fibrotic liver (B), and RGD-HBc NCs treated liver (C) at
preinjection (left) and 1 h after intravenous injection (right) of RGD-
HBc/QGd NCs. The contrast agent was injected at a dose of 0.05
mmol Gd/kg. (D) The quantification of MRI in different groups (1:
normal liver; 2: fibrotic liver; and 3: RGD-HBc NCs treated liver). (*
p < 0.05).
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Xiamen University, are free access to standard chow and water.
Mice were housed at temperatures of 20−28 °C, relative
humidity of 60−70% with ventilation, and 12 h light and dark
cycle. Group 1 (n = 5) served as controls and received only
pure olive oil. The hepatic fibrosis model was obtained by
intervening with CCl4. Generally, CCl4 was dissolved in olive
oil (1:4), and the mice in group 2 (n = 5) were injected
intraperitoneally with 200 μL of CCl4 solution twice a week for
8 weeks. Group 3 (n = 5) served as the treatment group, in
which RGD-HBc/QR NCs were injected via intravenous
injection once every 3 days for a month.
In Vivo Fluorescence Imaging. Through in vivo near-
infrared fluorescence imaging, the in vivo targeting effect and
cycle time of RGD-HBc NCs were visually observed. For oil
group mice and CCl4-treated group mice, 200 μL of RGD-HBc
NCs-Cy5.5 was injected through the tail vein and imaged at
0.3, 2, and 12 h. For in vitro imaging, mice were sacrificed at
0.3, 2, and 12 h after injection of RGD-HBc NCs-Cy5.5, and
the main organs of heart, liver, spleen, lung, and kidney were
observed via the imaging system.
In Vivo MR Imaging. MRI was performed on mice after
one month of treatment using 7.0 T Varian MRI system
(Agilent Technologies, U.S.A.) with a horizontal-bore Magnex
magnet, equipped with 10 cm bore imaging gradients (40 G·
cm−1). The testing parameters were adopted: TR (repetition
time) = 500 ms, TE (echo time) = 10 ms, slice thickness = 2
mm, FOV = 80 × 50, matrix = 256 × 256. The normal group,
the fibrotic group, and the treated group were subjected to
isoflurane anesthesia, and T1-weighted imaging images were
collected before injection. Thereafter, 100 μL of RGD-HBc/
QGd NCs (150 μg mL−1) was injected through the tail vein,
and T1 weighted imaging observation was performed at 2 h.
Statistical Analysis. Quantitative data were presented with
error bars as mean with SD (standard deviation). Comparisons
among groups were determined by one-way ANOVA analysis
followed by t test. Differences were considered significant if p <
0.05.
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